A Phase 3 interventional study of GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108) and ActHIB™ in Haemophilus Influenzae Type b, sponsored by GlaxoSmithKline. Completed at 63 sites in United States. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-12.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 6th largest by enrollment of the 80 interventional ones that give a count, is one of 8 that started in 2010, is one of 48 in phase 3, and was the 52nd registered.
176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.
Browse Haemophilus Infections studies →None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →
Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,003 is above the median of 458 across 163 interventional studies indexed under Haemophilus Infections.
Median enrollment 445 across the 80 interventional studies, 270 across the 2 observational. Of the 81 that completed or were terminated, 55 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate safety, to demonstrate lot-to-lot consistency of the vaccine, to address the relevant concomitant vaccine administrations and to provide a comparison between GSK Biologicals' Hib conjugate vaccine and the licensed monovalent Hib vaccine ActHIB as well as the licensed combination product Pentacel in infants at 2, 4, 6 and 15-18 months of age. This study is designed with a primary and a booster phase.
This protocol posting has been updated following protocol amendment 3, dated 12 April 2011. The impacted section is: Eligibility Criteria (Exclusion criteria).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pooled group of subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of 3 different lots of Hiberix® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age The Hiberix® vaccine was administered intramuscularly in the right thigh. Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
Biological: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108) · Biological: Pediarix™ · Biological: Prevnar 13™ · Biological: Rotarix™ · Biological: Infanrix™
Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of ActHIB® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The ActHIB® vaccine was administered intramuscularly in the right thigh. The Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
Biological: ActHIB™ · Biological: Pediarix™ · Biological: Prevnar 13™ · Biological: Rotarix™ · Biological: Infanrix™
Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of Pentacel® vaccine co-administered with 3 doses of Prevnar13® vaccine, 2 or 3 doses of Engerix™-B vaccine at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The Pentacel® vaccine was administered intramuscularly in the right thigh. The Engerix™-B vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally. If subjects in the Pentacel Group had received a birth dose of Hepatitis B vaccine then they were to receive Engerix™-B vaccine only at 2 and 6 months of age.
Biological: Pentacel™ · Biological: Prevnar 13™ · Biological: Rotarix™ · Biological: Engerix™-B
Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
Also known as: Hiberix®
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
Two oral doses in primary epoch at 2 and 4 months of age
Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
One dose in the booster epoch at 15-18 months of age as intramuscular injection
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0 µg/mL
Non-inferiority of Hiberix to ActHIB, each co-administered with Pediarix, Prevnar13 and Rotarix following 3 primary doses in terms of immune response to PRP (Anti-PRP≥ 0.15 µ g/ml and ≥1.0 µg/mL).
Time frame: At 1 month after last dose of primary vaccination
Number of Subjects With Anti-Protein-D (Anti-D) and Anti-Protein-T (Anti-T) Antibody Concentrations ≥ 0.1 International Units Per Milliliter (IU/mL)
Non-inferiority of Pediarix co-administered with Hiberix, Prevnar13 and Rotarix compared to Pediarix co-administered with ActHIB, Prevnar13 and Rotarix following 3 primary vaccine doses in terms of immune response to Diphtheria, Tetanus.
Time frame: At 1 month after last dose of primary vaccination
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL).
Time frame: At 1 month after last dose of primary vaccination
Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibody Concentrations
Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL.
Time frame: At 1 month after last dose of primary vaccination
Anti-Streptococcus Pneumoniae (S.Pneumoniae) Antibody Concentrations
Antibody concentrations against S.pneumoniae were given as geometric mean concentrations (GMCs) expressed as microgram per milliliter (µg/mL).
Time frame: At 1 month after last dose of primary vaccination
Number of Subjects With Seroresponse (95%) to Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA)
Seroresponse (95%) was defined as the number of subjects showing a concentration above a threshold that leads to 95% seroresponse in the ActHIB group.
Time frame: At 1 month after last dose of primary vaccination
Number of Subjects With Anti-Polio 1,2,3 Antibody Titres Greater Than or Equal to Cut-off Value
The cut-off value was defined as a concentration ≥ 8 ED50 (ED50 is the concentration at which the protein exhibits 50% of its maximum activity). The polio testing which started at the Biomnis laboratory was stopped because the polio virus micro-neutralization assays were found to be not in line with the quality standards defined in GSK Biologicals' SOPs. As a result, polio testing was restarted at the GSK laboratory and the results were uploaded into the clinical database.
Time frame: At 1 month after last dose of primary vaccination
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 1.0 µg/mL
Non-inferiority of a booster dose of Hiberix co-administered with Infanrix in subjects 15-18 months of age who received 3 primary vaccine doses of Hiberix to a booster dose of ActHIB co-administered with Infanrix in subjects of 15-18 months of age who received 3 primary vaccine doses of ActHIB in terms of immune response to PRP
Time frame: At 1 month after booster vaccination
Anti-protein-D (Anti-D) and Anti-protein-T (Anti-T) Antibody Concentrations
Antibody concentrations were given as geometric mean concentrations (GMCs) and expressed as International Units per milliliter (IU/mL).
Time frame: At 1 month after last dose of primary vaccination
Number of Subjects With Any Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade.
Time frame: During a 4-day follow-up period (Days 0-3) following any vaccination
Number of Subjects With Any Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Rectal temperature equal to or above (≥) 38 degrees Celsius (°C).
Time frame: During a 4-day follow-up period (Days 0-3) following any vaccination
Number of Subjects With Any Unsolicited Adverse Events (AEs).
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 31-day (Day 0-Day 30) follow-up period after primary vaccination
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Day 0 until 6 months following the last primary dose
Number of Subjects With AEs of Specific Interest (AESIs)
An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.
Time frame: From Day 0 until 6 months following the last primary dose or the receipt of the booster vaccination, whichever comes first
Number of Subjects With Seroresponse (90%) to Anti-PT, Anti-PRN and Anti-FHA
Seroresponse (90%) was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group.
Time frame: At 1 month after last dose of primary vaccination
Number of Subjects With Anti-PT, Anti-PRN and Anti-FHA Antibody Concentrations ≥ 5 EL.U/mL
Seroresponse was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group.
Time frame: At 1 month after last dose of primary vaccination
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 0.15 µg/mL and ≥ 1.0 µg/mL
Evaluation of persistence of anti-PRP antibodies induced by three primary vaccine doses of Hiberix, and ActHIB, each co-administered with Pediarix, Prevnar 13 and Rotarix, or Pentacel co-administered with Engerix-B, Rotarix and Prevnar 13 prior to the booster dose of Hiberix, ActHIB or Pentacel at 15-18 months of age and evaluation of immunogenicity of a booster dose of Hiberix co-administered with Infanrix, ActHIB co-administered with Infanrix and Pentacel in terms of the percentage of subjects with anti-PRP concentrations ≥0.15 µg/mL, ≥1.0 µg/mL and GMCs one month after the booster dose.
Time frame: Prior to the booster vaccination and 1 month after the booster vaccination
Anti-Hepatitis B (Anti-HBs) Antibody Concentrations
Antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressedas milli-international units per milliliter (mIU/mL).
Time frame: At 1 month after last dose of primary vaccination
Number of Subjects With S.Pneumoniae Antibody Concentrations ≥ 0.05 µg/mL, ≥ 0.2 µg/mL and ≥1.0 µg/mL
Evaluation of immunogenicity of a 3-dose primary vaccination course of Prevnar 13 co-administered with Hiberix, Rotarix and Pediarix, of Prevnar 13 co-administered with ActHIB, Rotarix and Pediarix and of Prevnar 13 co-administered with Pentacel, Rotarix and Engerix-B in terms of S.pneumoniae GMCs and antibody concentrations ≥ 0.05µg/mL, ≥ 0.2 µg/mL, ≥ 1.0 µg/mL at one month after the last dose of primary vaccination.
Time frame: At 1 month after the last dose of primary vaccination
Antibody Titers for Poliovirus Types 1, 2 and 3
Antibody titers were given as geometric mean titers(GMTs).
Time frame: At 1 month after last dose of primary vaccination
Number of Subjects With Anti-HBs Antibody Concentrations Greater Than or Equal to Cut-off Values
The cut-off values were defined as a concentration≥ 3.3 mIU/mL (seropositivity) and ≥ 10 mIU/mL (seroprotection).
Time frame: At 1 month after last dose of primary vaccination
Anti-polyribosylribitol Phosphate (PRP) Antibody Concentrations
Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL).
Time frame: Prior to the booster vaccination and 1 month after the booster vaccination
Anti-Hepatitis B (Anti-HBs) Antibody Concentrations ≥10.0 mIU/mL and ≥6.2 mIU/mL
Antibody concentrations were expressed as geometric mean concentrations (GMCs) and expressed as milli-international units per milliliter (mIU/mL).
Time frame: Prior to the booster vaccination
Number of Subjects With Anti-HB Antibody Concentrations ≥10.0 mlU/mL and ≥6.2mLU/mL
The cut-off values were defined as a concentration≥ 6.2 mIU/mL (seropositivity) and ≥ 10 mIU/mL (seroprotection).
Time frame: Prior to booster vaccination
Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Concentrations ≥ 5 EL.U/mL
Evaluation of persistence of anti-PT, anti-FHA and anti-PRN antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-PT, anti-FHA and anti- PRN antibodies.
Time frame: Prior to the booster vaccination and 1 month after the booster vaccination
Anti-poliovirus Types 1, 2, and 3 Antibody Titres and Titres ≥ 8
Antibody concentrations were tabulated as geometric mean titers (GMTs) and expressed as titers.
Time frame: Prior to the booster vaccination
Number of Subjects With Anti-Polio-1,2,3 Antibody Titers ≥ 8
Anti-polio 1,2,3 antibody titers greater or equal to the cut off value were calculated.
Time frame: Prior to booster vaccination
Number of Subjects With Anti-D and Anti-T Antibody Concentrations ≥ 0.1 IU/mL and ≥1.0 IU/mL, Respectively.
Evaluation of persistence of anti-D, anti-T antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-D and anti-T antibodies.
Time frame: Prior to the booster vaccination and 1 month after the booster vaccination
Number of Subjects With Any Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade.
Time frame: Within 4 days (Days 0-3) following the booster dose
Number of Subjects With Any Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Axillary temperature equal to or above (≥) 38 degrees Celsius (°C).
Time frame: Within 4 days (Days 0-3) following the booster dose
Number of Subjects With AEs of Specific Interest (AESIs)
An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.
Time frame: From booster dose until 6 months following receipt of the booster dose
Number of Subjects With Any Unsolicited Adverse Events (AEs).
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within 31 days (Day 0 to Day 30) following the booster dose
Number of Subjects With Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From the booster dose until 6 months following receipt of the booster dose
Anti-FHA, Anti-PRN and Anti-PT Antibody Concentrations
Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL.
Time frame: pre-booster and one month after booster vaccination
| Milestone | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Started | 2963 | 520 | 520 |
| Completed | 2625 | 470 | 457 |
| Not completed | 338 | 50 | 63 |
| Withdrew: Withdrawal by subject | 109 | 17 | 21 |
| Withdrew: Lost to follow-up | 171 | 19 | 26 |
| Withdrew: Protocol violation | 40 | 3 | 2 |
| Withdrew: Adverse event | 14 | 2 | 2 |
| Withdrew: Other | 4 | 9 | 12 |
| Milestone | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Started | 2337 | 435 | 400 |
| Completed | 2270 | 423 | 386 |
| Not completed | 67 | 12 | 14 |
| Withdrew: Protocol violation | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 |
| Withdrew: Lost to follow-up | 40 | 5 | 7 |
| Withdrew: Other | 24 | 6 | 4 |
Non-inferiority of Hiberix to ActHIB, each co-administered with Pediarix, Prevnar13 and Rotarix following 3 primary doses in terms of immune response to PRP (Anti-PRP≥ 0.15 µ g/ml and ≥1.0 µg/mL).
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-PRP ≥ 0.15 µg/mL | 1536 | 265 | 234 |
| Anti-PRP ≥ 1.0 µg/mL | 1291 | 246 | 198 |
Non-inferiority of Pediarix co-administered with Hiberix, Prevnar13 and Rotarix compared to Pediarix co-administered with ActHIB, Prevnar13 and Rotarix following 3 primary vaccine doses in terms of immune response to Diphtheria, Tetanus.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-D | 393 | 273 | 249 |
| Anti-T | 393 | 274 | 249 |
Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL).
| µg/mL | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations | 5.193 (4.765 to 5.658) | 6.743 (5.593 to 8.129) | 3.640 (2.891 to 4.583) |
Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL.
| EL.U/mL | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-PT | 73.2 (69.8 to 76.6) | 71.9 (66.6 to 77.6) | 41.9 (38.4 to 45.8) |
| Anti-PRN | 111.6 (104.5 to 119.2) | 93.5 (83.7 to 104.4) | 51.9 (45.4 to 59.3) |
| Anti-FHA | 321.8 (307.0 to 337.3) | 295.8 (276.0 to 317.0) | 174.8 (160.0 to 191.0) |
Antibody concentrations against S.pneumoniae were given as geometric mean concentrations (GMCs) expressed as microgram per milliliter (µg/mL).
| µg/mL | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-Pneumoniae 1 | 2.515 (2.318 to 2.729) | 2.500 (2.278 to 2.745) | 2.442 (2.190 to 2.722) |
| Anti-Pneumoniae 3 | 1.056 (0.976 to 1.142) | 1.008 (0.933 to 1.089) | 1.190 (1.066 to 1.329) |
| Anti-Pneumoniae 4 | 1.804 (1.684 to 1.932) | 1.803 (1.662 to 1.957) | 1.819 (1.645 to 2.011) |
| Anti-Pneumoniae 5 | 3.729 (3.409 to 4.079) | 3.656 (3.308 to 4.040) | 3.530 (3.128 to 3.984) |
| Anti-Pneumoniae 6A | 3.442 (3.177 to 3.729) | 3.340 (3.032 to 3.679) | 3.384 (3.046 to 3.760) |
| Anti-Pneumoniae 6B | 1.065 (0.950 to 1.196) | 0.994 (0.860 to 1.148) | 0.875 (0.757 to 1.013) |
| Anti-Pneumoniae 7F | 4.518 (4.192 to 4.870) | 4.115 (3.777 to 4.484) | 3.785 (3.412 to 4.199) |
| Anti-Pneumoniae 9V | 2.516 (2.305 to 2.746) | 2.431 (2.204 to 2.681) | 2.226 (1.976 to 2.507) |
| Anti-Pneumoniae 14 | 4.506 (4.105 to 4.946) | 4.111 (3.672 to 4.602) | 3.938 (3.472 to 4.466) |
| Anti-Pneumoniae 18C | 3.655 (3.351 to 3.986) | 3.507 (3.196 to 3.848) | 3.401 (3.033 to 3.814) |
| Anti-Pneumoniae 19A | 1.556 (1.433 to 1.689) | 1.553 (1.391 to 1.735) | 1.321 (1.175 to 1.486) |
| Anti-Pneumoniae 19F | 2.745 (2.552 to 2.952) | 2.833 (2.613 to 3.072) | 2.531 (2.315 to 2.766) |
| Anti-Pneumoniae 23F | 2.046 (1.846 to 2.267) | 1.985 (1.765 to 2.232) | 1.670 (1.444 to 1.931) |
Seroresponse (95%) was defined as the number of subjects showing a concentration above a threshold that leads to 95% seroresponse in the ActHIB group.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-PT | 764 | 264 | 201 |
| Anti-PRN | 762 | 262 | 213 |
| Anti-FHA | 744 | 263 | 191 |
The cut-off value was defined as a concentration ≥ 8 ED50 (ED50 is the concentration at which the protein exhibits 50% of its maximum activity). The polio testing which started at the Biomnis laboratory was stopped because the polio virus micro-neutralization assays were found to be not in line with the quality standards defined in GSK Biologicals' SOPs. As a result, polio testing was restarted at the GSK laboratory and the results were uploaded into the clinical database.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-Polio 1 | 246 | 181 | 164 |
| Anti-Polio 2 | 275 | 188 | 183 |
| Anti-Polio 3 | 254 | 181 | 168 |
Non-inferiority of a booster dose of Hiberix co-administered with Infanrix in subjects 15-18 months of age who received 3 primary vaccine doses of Hiberix to a booster dose of ActHIB co-administered with Infanrix in subjects of 15-18 months of age who received 3 primary vaccine doses of ActHIB in terms of immune response to PRP
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 1.0 µg/mL | 333 | 231 | 184 |
Antibody concentrations were given as geometric mean concentrations (GMCs) and expressed as International Units per milliliter (IU/mL).
| IU/mL | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-D | 2.72 (2.54 to 2.93) | 2.45 (2.24 to 2.68) | 1.88 (1.69 to 2.09) |
| Anti-T | 2.23 (2.07 to 2.41) | 2.44 (2.20 to 2.71) | 1.72 (1.55 to 1.91) |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Any pain | 1932 | 366 | 370 |
| Any redness | 1165 | 233 | 257 |
| Any swelling | 834 | 174 | 195 |
Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Rectal temperature equal to or above (≥) 38 degrees Celsius (°C).
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Any drowsiness | 2179 | 398 | 378 |
| Any irritability | 2478 | 449 | 434 |
| Any loss of appetite | 1450 | 275 | 253 |
| Any fever | 1014 | 186 | 143 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs). | 1880 | 350 | 324 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 108 | 24 | 21 |
An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With AEs of Specific Interest (AESIs) | 108 | 22 | 15 |
Seroresponse (90%) was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-PT | 706 | 248 | 165 |
| Anti-PRN | 741 | 250 | 194 |
| Anti-FHA | 705 | 248 | 166 |
Seroresponse was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-PT | 789 | 275 | 249 |
| Anti-PRN | 786 | 275 | 244 |
| Anti-FHA | 791 | 275 | 249 |
Evaluation of persistence of anti-PRP antibodies induced by three primary vaccine doses of Hiberix, and ActHIB, each co-administered with Pediarix, Prevnar 13 and Rotarix, or Pentacel co-administered with Engerix-B, Rotarix and Prevnar 13 prior to the booster dose of Hiberix, ActHIB or Pentacel at 15-18 months of age and evaluation of immunogenicity of a booster dose of Hiberix co-administered with Infanrix, ActHIB co-administered with Infanrix and Pentacel in terms of the percentage of subjects with anti-PRP concentrations ≥0.15 µg/mL, ≥1.0 µg/mL and GMCs one month after the booster dose.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-PRP ≥ 0.15 µg/mL; PRE vaccination | 247 | 172 | 116 |
| Anti-PRP ≥ 0.15 µg/mL; POST vaccination | 336 | 235 | 186 |
| Anti-PRP ≥ 1 µg/mL; PRE vaccination | 106 | 61 | 44 |
| Anti-PRP ≥ 1 µg/mL; POST vaccination | 333 | 231 | 184 |
Antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressedas milli-international units per milliliter (mIU/mL).
| mIU/mL | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-Hepatitis B (Anti-HBs) Antibody Concentrations | 3684.3 (3287.0 to 4129.5) | 3545.6 (3067.8 to 4098.0) | 1573.4 (1302.6 to 1900.6) |
Evaluation of immunogenicity of a 3-dose primary vaccination course of Prevnar 13 co-administered with Hiberix, Rotarix and Pediarix, of Prevnar 13 co-administered with ActHIB, Rotarix and Pediarix and of Prevnar 13 co-administered with Pentacel, Rotarix and Engerix-B in terms of S.pneumoniae GMCs and antibody concentrations ≥ 0.05µg/mL, ≥ 0.2 µg/mL, ≥ 1.0 µg/mL at one month after the last dose of primary vaccination.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| ≥ 0.05 µg/mL, Anti-Pneumoniae 1 | 384 | 268 | 245 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 3 | 382 | 269 | 243 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 4 | 389 | 268 | 247 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 5 | 379 | 266 | 246 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 6A | 381 | 267 | 244 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 6B | 378 | 260 | 241 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 7F | 386 | 269 | 246 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 9V | 385 | 270 | 246 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 14 | 384 | 267 | 244 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 18C | 380 | 267 | 244 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 19A | 383 | 265 | 244 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 19F | 384 | 268 | 245 |
| ≥ 0.05 µg/mL, Anti-Pneumoniae 23F | 384 | 267 | 244 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 1 | 382 | 267 | 244 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 3 | 379 | 268 | 243 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 4 | 389 | 267 | 247 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 5 | 377 | 265 | 245 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 6A | 379 | 265 | 243 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 6B | 351 | 242 | 224 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 7F | 386 | 269 | 246 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 9V | 385 | 269 | 243 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 14 | 381 | 265 | 241 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 18C | 377 | 267 | 244 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 19A | 379 | 259 | 235 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 19F | 383 | 267 | 244 |
| ≥ 0.2 µg/mL, Anti-Pneumoniae 23F | 376 | 265 | 231 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 1 | 334 | 239 | 213 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 3 | 188 | 140 | 138 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 4 | 318 | 226 | 199 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 5 | 354 | 250 | 225 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 6A | 357 | 253 | 229 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 6B | 232 | 151 | 117 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 7F | 379 | 264 | 239 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 9V | 338 | 234 | 203 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 14 | 360 | 250 | 223 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 18C | 361 | 256 | 229 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 19A | 290 | 200 | 164 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 19F | 357 | 254 | 231 |
| ≥ 1.0 µg/mL, Anti-Pneumoniae 23F | 297 | 208 | 180 |
Antibody titers were given as geometric mean titers(GMTs).
| Titers | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-Polio 1 | 570.8 (509.2 to 639.8) | 620.9 (540.1 to 713.7) | 136.0 (114.7 to 161.1) |
| Anti-Polio 2 | 471.8 (416.7 to 534.1) | 389.9 (337.3 to 450.6) | 210.9 (181.9 to 244.5) |
| Anti-Polio 3 | 982.8 (870.1 to 1110.2) | 963.2 (843.7 to 1099.5) | 297.4 (253.3 to 349.1) |
The cut-off values were defined as a concentration≥ 3.3 mIU/mL (seropositivity) and ≥ 10 mIU/mL (seroprotection).
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-HBs≥ 3.3 mIU/ml | 362 | 257 | 239 |
| Anti-HBs≥ 10 mIU/ml | 362 | 257 | 239 |
Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL).
| µg/mL | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| PRE | 0.498 (0.422 to 0.588) | 0.467 (0.385 to 0.567) | 0.380 (0.299 to 0.484) |
| POST | 48.782 (42.000 to 56.659) | 40.293 (33.386 to 48.630) | 37.543 (30.535 to 46.158) |
Antibody concentrations were expressed as geometric mean concentrations (GMCs) and expressed as milli-international units per milliliter (mIU/mL).
| mIU/mL | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-Hepatitis B (Anti-HBs) Antibody Concentrations ≥10.0 mIU/mL and ≥6.2 mIU/mL | 268.3 (226.7 to 317.5) | 247.0 (199.8 to 305.3) | 156.4 (117.9 to 207.5) |
The cut-off values were defined as a concentration≥ 6.2 mIU/mL (seropositivity) and ≥ 10 mIU/mL (seroprotection).
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-HBs ≥ 6.2 mIU/mL | 311 | 199 | 156 |
| Anti-HBs ≥10.0 mIU/mL | 306 | 198 | 154 |
Evaluation of persistence of anti-PT, anti-FHA and anti-PRN antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-PT, anti-FHA and anti- PRN antibodies.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-FHA, PRE | 328 | 223 | 171 |
| Anti-FHA, POST | 335 | 235 | 185 |
| Anti-PRN, PRE | 279 | 174 | 130 |
| Anti-PRN, POST | 331 | 233 | 185 |
| Anti-PT, PRE | 243 | 168 | 81 |
| Anti-PT, POST | 335 | 235 | 186 |
Antibody concentrations were tabulated as geometric mean titers (GMTs) and expressed as titers.
| Titers | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-polio 1 | 106.2 (91.1 to 123.8) | 101.6 (84.4 to 122.3) | 25.1 (20.3 to 31.0) |
| Anti-polio 2 | 109.4 (92.8 to 129.1) | 89.5 (73.4 to 109.1) | 48.9 (39.7 to 60.2) |
| Anti-polio 3 | 154.8 (129.3 to 185.3) | 151.9 (122.4 to 188.5) | 40.6 (31.4 to 52.5) |
Anti-polio 1,2,3 antibody titers greater or equal to the cut off value were calculated.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-polio 1 | 294 | 197 | 124 |
| Anti-polio 2 | 285 | 196 | 144 |
| Anti-polio 3 | 283 | 201 | 130 |
Evaluation of persistence of anti-D, anti-T antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-D and anti-T antibodies.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-D≥ 0.1 IU/mL, PRE | 322 | 218 | 173 |
| Anti-D≥ 0.1 IU/mL, POST | 336 | 236 | 186 |
| Anti-T≥ 0.1 IU/mL, PRE | 292 | 196 | 154 |
| Anti-T≥ 0.1 IU/mL, POST | 336 | 236 | 186 |
| Anti-D≥1.0 IU/mL , PRE | 151 | 89 | 70 |
| Anti-D≥1.0 IU/mL , POST | 334 | 234 | 186 |
| Anti-T≥1.0 IU/mL , PRE | 52 | 27 | 14 |
| Anti-T≥1.0 IU/mL , POST | 330 | 233 | 180 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Any Pain | 918 | 179 | 163 |
| Any Redness | 659 | 127 | 115 |
| Any Swelling | 392 | 82 | 75 |
Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Axillary temperature equal to or above (≥) 38 degrees Celsius (°C).
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Any Drowsiness | 857 | 164 | 119 |
| Any Irritability | 1293 | 250 | 201 |
| Any Loss of appetite | 614 | 141 | 85 |
| Any Fever | 119 | 18 | 20 |
An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With AEs of Specific Interest (AESIs) | 47 | 12 | 7 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs). | 882 | 159 | 138 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Subjects | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 29 | 4 | 2 |
Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL.
| EL.U/mL | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Anti-FHA, PRE | 41.3 (37.4 to 45.6) | 40.0 (35.2 to 45.5) | 22.7 (20.0 to 25.7) |
| Anti-FHA, POST | 464.9 (430.0 to 502.7) | 492.5 (449.0 to 540.3) | 263.8 (239.5 to 290.5) |
| Anti-PRN, PRE | 13.3 (12.0 to 14.8) | 11.2 (9.8 to 12.9) | 9.7 (8.3 to 11.3) |
| Anti-PRN, POST | 288.9 (260.4 to 320.5) | 259.2 (225.6 to 297.7) | 153.2 (128.5 to 182.6) |
| Anti-PT, PRE | 8.5 (7.7 to 9.3) | 8.6 (7.7 to 9.7) | 4.8 (4.2 to 5.3) |
| Anti-PT, POST | 90.9 (83.9 to 98.4) | 93.1 (84.1 to 103.1) | 75.3 (66.7 to 85.1) |
Collected over SAEs= Day 0 to 6 months following last primary dose and from booster dose until 6 months after receipt of booster dose. Systematically and non-systematically assessed frequent AEs=within 4 and 31 days following primary and booster vaccination respectively. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hiberix Group | — | 120/2,963 (4%) | 2,783/2,963 (93.9%) |
| ActHIB Group | — | 24/520 (4.6%) | 495/520 (95.2%) |
| Pentacel Group | — | 21/520 (4%) | 488/520 (93.8%) |
| Event | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| Respiratory syncytial virus bronchiolitisInfections and infestations | 13/2963 | 4/520 | 2/520 |
| DehydrationMetabolism and nutrition disorders | 10/2963 | 3/520 | 1/520 |
| Febrile convulsionNervous system disorders | 8/2963 | 3/520 | 0/520 |
| BronchiolitisInfections and infestations | 16/2963 | 2/520 | 2/520 |
| PneumoniaInfections and infestations | 14/2963 | 2/520 | 2/520 |
| Croup infectiousInfections and infestations | 4/2963 | 0/520 | 2/520 |
| Otitis mediaInfections and infestations | 10/2963 | 0/520 | 2/520 |
| Respiratory syncytial virus infectionInfections and infestations | 9/2963 | 2/520 | 0/520 |
| Subcutaneous abscessInfections and infestations | 3/2963 | 2/520 | 0/520 |
| Upper respiratory tract infectionInfections and infestations | 2/2963 | 2/520 | 0/520 |
| Event | Hiberix Group | ActHIB Group | Pentacel Group |
|---|---|---|---|
| IrritabilityPsychiatric disorders | 2525/2963 | 459/520 | 441/520 |
| SomnolenceNervous system disorders | 2235/2963 | 409/520 | 387/520 |
| PainGeneral disorders | 2035/2963 | 380/520 | 383/520 |
| Decreased appetiteMetabolism and nutrition disorders | 1596/2963 | 304/520 | 272/520 |
| ErythemaSkin and subcutaneous tissue disorders | 1306/2963 | 262/520 | 277/520 |
| PyrexiaGeneral disorders | 1288/2963 | 240/520 | 201/520 |
| SwellingGeneral disorders | 944/2963 | 191/520 | 211/520 |
| Upper respiratory tract infectionInfections and infestations | 655/2963 | 109/520 | 105/520 |
| CoughRespiratory, thoracic and mediastinal disorders | 369/2963 | 64/520 | 73/520 |
| Otitis mediaInfections and infestations | 355/2963 | 63/520 | 61/520 |
| Age, Continuous(Weeks) | Hiberix Group | ActHIB Group | Pentacel Group | Total |
|---|---|---|---|---|
| Mean | 8.6 ± 1.08 | 8.6 ± 1.13 | 8.7 ± 1.12 | 8.61 ± 1.09 |
| Sex: Female, Male(Participants) | Hiberix Group | ActHIB Group | Pentacel Group | Total |
|---|---|---|---|---|
| Female | 1424 | 271 | 258 | 1953 |
| Male | 1539 | 249 | 262 | 2050 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
The record gives a start of Jun 2010, a primary completion of Nov 2011 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Hiberix · Pediarix